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Abstract
Background: Chronic arterial stiffness contributes to the negative health effects of obesity and insulin resistance,
which include hypertension, stroke, and increased cardiovascular and all-cause mortality. Weight loss and improved
insulin sensitivity are individually associated with improved central arterial stiffness; however, their combined effects
on arterial stiffness are poorly understood. The purpose of this study was to determine how insulin levels modify
the improvements in arterial stiffness seen with weight loss in overweight and obese young adults.
Methods: To assess the effects of weight loss and decreased fasting insulin on vascular stiffness, we studied 339
participants in the Slow the Adverse Effects of Vascular Aging (SAVE) trial. At study entry, the participants were aged
20–45, normotensive, non-diabetic, and had a body-mass index of 25–39.9 kg/m2. Measures of pulse wave velocity
(PWV) in the central (carotid-femoral (cfPWV)), peripheral (femoral-ankle (faPWV)), and mixed (brachial-ankle
(baPWV)) vascular beds were collected at baseline and 6 months. The effects of 6-month change in weight and
insulin on measures of PWV were estimated using multivariate regression.
Results: After adjustment for baseline risk factors and change in systolic blood pressure, 6-month weight loss and
6-month change in fasting insulin independently predicted improvement in baPWV but not faPWV or cfPWV. There
was a significant interaction between 6-month weight change and change in fasting insulin when predicting
changes in baPWV (p < 0.001). Individuals experiencing both weight loss and insulin reductions showed the
greatest improvement in baPWV.
Conclusions: Young adults with excess weight who both lower their insulin levels and lose weight see the greatest
improvement in vascular stiffness. This improvement in vascular stiffness with weight loss and insulin declines may
occur throughout the vasculature and may not be limited to individual vascular beds.
Trial registration: NCT00366990
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Background
Paramount among the negative health effects of obesity
and insulin resistance (IR) are their adverse effects on
vascular health [1]. Arterial stiffness is a measure of vas-
cular health and its progression is accelerated in both
obesity and IR [2,3]. Chronic arterial stiffness eventually
disrupts the hemodynamics of the vasculature, contrib-
uting to hypertension, stroke, and both cardiovascular
and all-cause mortality [4].
Pulse wave velocity (PWV) is a non-invasive measure
of arterial stiffness. Higher values are associated with
greater stiffness. Weight loss is associated with reduc-
tions in PWV, independent of baseline weight [5].
These findings were recently replicated in the Slow
Adverse Vascular Effects (SAVE) clinical trial, prelimin-
ary results from which demonstrate that a weight loss
and physical activity intervention can reduce arterial
stiffness in young adults with excess weight [6].
Weight loss also directly reduces insulin levels and IR
[7]. Emerging research indicates that obesity alone may
not pose short term risk of cardiovascular events, and
that IR may be a key factor in the obese individual’s
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increased risk for cardiovascular disease [8]. While
weight loss [5] and increased insulin sensitivity [2] are
individually associated with improved central arterial
stiffness, their combined effects on the aorta and other
arterial segments are poorly understood. Understanding
the contributions of weight loss and improved insulin
sensitivity to arterial stiffness will provide insight into
sub-clinical vascular changes preceding and potential-
ly contributing to complications of diabetes and
hypertension.
Recent work from our group explored potential pre-
dictors of change in pulse-wave velocity and found
that changes in BMI, heart rate and C-reactive protein
were associated with changes in PWV [9]. However,
these analyses did not assess the effects of changes in
insulin and weight on PWV. The purpose of this ana-
lysis was to specifically examine the combined effects
of reduction in both weight and insulin on changes in
pulse wave velocity measured in various arterial loca-
tions in young overweight, sedentary adults engaged in
a weight loss intervention. We hypothesized that: 1)
weight loss and insulin reductions would independently
be associated with reductions in pulse wave velocity
measured across various arterial sites, and 2) the com-
bined effect of weight loss and insulin reductions
would be significantly related to improvements in
pulse wave velocity.
Methods
SAVE population
This study consists of 339 healthy men and women who
had viable measures of baseline PWV and additional in-
formation on covariates from the 349 subjects who par-
ticipated in the SAVE clinical trial (NCT00366990).
Methods of participant recruitment and intervention in
the SAVE trial were previously reported [10]. Briefly,
SAVE is a randomized controlled trial examining the
effects of weight reduction, physical activity and dietary
sodium reduction on improving vascular health. Partici-
pants were 25 – 45 year-old men and women from Alle-
gheny County, PA, who were physically inactive and
overweight to class II obese. Exclusion criteria for SAVE
included: 1) diabetes, defined as fasting blood glucose
≥126 mg/dl; 2) hypertension, defined as average screen-
ing blood pressure ≥ 140/90 mmHg or any treatment
with antihypertensive medications; 3) current use of
cholesterol-lowering, antipsychotic, or vasoactive medi-
cines or devices; 4) any underlying inflammatory condi-
tion; 5) known atherosclerotic disease; and 6) pregnancy,
breastfeeding, or plans for pregnancy during the study
period. All study participants signed an informed con-
sent document approved by the University of Pittsburgh
Institutional Review Board.
Main outcomes
Pulse wave velocity was assessed at the University of
Pittsburgh Ultrasound Research Laboratory (Pittsburgh,
PA, US) using a noninvasive and automated waveform
analyzer (Colin Co., Komaki, Japan) [11]. All measures
were performed in a quiet temperature-controlled room
after a 12 hour fast and abstinence from caffeine. Indivi-
duals were also asked to refrain from vigorous exercise
thirty minutes prior to testing.
Resting blood pressure was measured twice after a
10 minute rest using an automated device. Blood pres-
sure cuffs were attached to both uncovered arms and
ankles using appropriate cuff sizes. Electrocardiogram
clips were attached to both wrists. A phonocardiogram
was held in place with a two pound weight at the fourth
intercostal space to the left of the sternum, and tonome-
try sensors were manually placed on the left carotid and
femoral arteries.
PWV was measured in the central (carotid-femoral
(cfPWV), peripheral (femoral-ankle (faPWV)), and
mixed (brachial-ankle (baPWV)) vascular beds. PWV is
calculated as the distance in centimeters between arterial
sites of interest over time (in seconds) that the pressure
waveforms travel from the heart to the respective arterial
sites. Distance for cfPWV was calculated by subtracting
the distance from the carotid artery to suprasternal
notch from the sum of the distances between supraster-
nal notch to the inferior edge of the umbilicus and from
the inferior edge of the umbilicus to the femoral artery.
Distances between peripheral sites were calculated using
a height based algorithm as required by the Colin
waveform analyzer [11]. Time was calculated using the
foot-to-foot velocity method of waveforms measured at
various sites [12]. The average of two runs was used
in this analysis. The validity and reliability of pulse wave
velocity assessment with this device has been previously
reported [13]. Ultrasound Research Laboratory staff
determined the reproducibility of PWV measures, using
intraclass correlation coefficients (ICC). ICC was higher
for baPWV (ICC= 0.97) and faPWV (ICC= 0.96) com-
pared to cfPWV (ICC=0.75).
Main predictors
Insulin was measured using standard radio-immune
assay (Linco Research, St. Charles, MO). Insulin change
was calculated as the difference in insulin levels from
baseline to 6 months follow-up. HOMA-IR, which is a
measured of insulin resistance, was calculated as (glu-
cose x insulin)/405 [14].
Research staff measured weight on the same standard
balance beam scale at each visit. Participants were
instructed to fast, empty their bladders and remove their
shoes, jackets, and heavy sweaters before being weighed.
Weights were rounded up to the nearest 1/10 of a
Hughes et al. Cardiovascular Diabetology 2012, 11:114 Page 2 of 8
http://www.cardiab.com/content/11/1/114
kilogram. Weight change was the difference in weight
from baseline to 6 months follow-up. BMI was calcu-
lated for each study visit as weight in kilograms divided
by height in meters squared.
Covariates
Self-reported information was collected from partici-
pants regarding age, gender, race, and smoking status.
Staff measured height and blood pressure using standar-
dized protocols. Blood pressures were measured using a
conventional manual mercury sphygmomanometer. Staff
measured the diameter of the midpoint of the right
upper arm to determine correct cuff size. Participants
rested for 5 minutes with uncrossed arms and feet flat
on the floor, and were instructed not to speak during the
rest period or blood pressure measurement. Readings
were taken with participants sitting with their arm ele-
vated, so that the blood pressure cuff was at heart level.
After staff determined the maximum inflation level, they
used the bell of the stethoscope to identify the first and
fifth Korotkoff sounds. The latter 2 of 3 readings taken
at least 30 seconds apart were averaged together. Mean
arterial pressures (MAP) was calculated as:
MAP ¼ 1=3ð Þ  averaged SBPþ 2=3ð Þ
 averaged DBP
Laboratory assays were performed on fasting serum
samples at the Heinz Laboratory at the University
of Pittsburgh’s Graduate School of Public Health
(Pittsburgh, PA, USA). Total cholesterol [15], high dens-
ity lipoprotein (HDLc) [16], low density lipoprotein
(LDLc) [17], and glucose were determined using stand-
ard laboratory procedures. C-reactive protein was mea-
sured with an enzyme-linked immunoassay (Alpha
Diagnostics International, Inc. San Antonio, TX).
Statistical methods
Variables with normal distributions are presented as
mean ± SD; variables with skewed distributions are pre-
sented as median [inter-quartile range]. Longitudinal
changes in PWV are reported as mean ± SD as well as
percentage change from baseline measurement. T-tests
were used to test for differences in longitudinal PWV by
gender and baseline fasting insulin levels.
Since the primary aim of this analysis was to deter-
mine if participants with both weight loss and reduction
in insulin over six months had a greater combined effect
on changes in pulse-wave velocity than those without
change in either, we performed a post-hoc power calcu-
lation and determined we had 80% power to detect at
least a 38 cm/sec difference between the individuals with
the combined effect weight loss and insulin reductions
and those without.
Six month change in weight, insulin and PWV was calcu-
lated by subtracting the six month value from baseline
values. Simple linear regression was used to estimate the
univariate effects of change in weight and change in insulin
on PWV in each arterial bed (Model 1). Multiple regression
analysis was used to estimate the simultaneous effects of
change in weight and insulin on change in PWV separately
for each of the three PWV outcomes (Model 2). Potential
covariates were then forced into the multiple regression
model to adjust for baseline differences and changing in
mean arterial pressure. After adjusting for baseline age, sex,
race, smoking status, BMI, MAP, HDLc, triglycerides, CRP,
fasting insulin, PWV and 6-month change in MAP, a mul-
tiple linear regression analysis was performed to identify
any independent associations between weight loss, change
in insulin level, and change in PWV. In order to assess the
combined effect of weight loss and insulin reductions on
changes in PWV, we added an interaction term to models
where weight loss and insulin reductions were simultan-
eously associated with changes in PWV (Model 3). We re-
ran the models of cfPWV after removing potential outliers
(e.g. two individuals with change in cfPWV>400 cm/sec)
and determined that inclusion of outlying values had no ef-
fect on these models.
In a separate model, we adjusted for SAVE intervention
assignment; however, the randomized treatment had no
effect on the reported relationships and is not reported
here. In sensitivity analyses, we reassessed each model of
PWV with HOMA-IR change as a predictor in place of in-
sulin change, and found insulin levels to be a stronger pre-
dictor of changes in PWV than HOMA-IR. All models
presented in this paper report changes in insulin levels. In-
sulin is reported as the primary predictor because it
explained more of the variance in PWV measures than
HOMA-IR in the SAVE trial of individual with fasting glu-
cose levels within the normal range. All statistical analyses
were performed using SAS statistical software release 9.2
(SAS Institute Inc., Cary, NC).
Results
Baseline characteristics for participants by gender are
displayed in (Table 1). Participants had a mean age of
37.9 years (range 21–46 years) and ranged from over-
weight to class II obese (mean BMI 32.8 kg/m2) with a
mean weight of 92.2 kg. The sample was predominantly
female (77.0%), white (80.5%) and never smokers
(62.2%). Age and BMI did not differ between genders.
Men were also more likely to be white and never smo-
kers than women (P = 0.013 and 0.067, respectively).
Fasting glucose, mean SBP and mean diastolic blood
pressure (DBP) were within normal ranges in the overall
sample, consistent with study entry criteria. However,
the men had significantly greater fasting glucose, SBP
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and DBP than women at baseline (P < 0.05 for all), even
though they were within normal values.
Other cardiovascular risk factors were not as optimal
as glucose and blood pressure Table 1. Despite being a
non-diabetic cohort, participants had elevated baseline
insulin levels and HOMA-IR. Total cholesterol, LDLc
and C-reactive protein (CRP) were also at the high end
of the normal ranges. Men recruited into SAVE tended
to have a more adverse cardiometabolic risk profile than
women in SAVE, with significantly higher glucose,
HOMA-IR, SBP, DBP, MAP and triglycerides and lower
HDLc than women. Only CRP was more adverse in
women. Men had greater baseline PWV than women in
all arterial beds except for faPWV. Brachial-ankle PWV
differed most between genders at baseline (48 cm/s
higher in men on average compared to women,
P < 0.001). The measures of baseline arterial stiffness
were significantly correlated with one another (baPWV
and faPWV, r = 0.69, p = <0.001; baPWV and cfPWV,
r = 0.30, p = <0.001; faPWV and cfPWV, r = 0.10,
p = 0.084).
Both men and women lost weight and decreased their
insulin levels over the 6 month intervention. Men lost
an average of 9.3 kg of weight and 2.5 μU/mL of insulin
compared with an average loss of 5.8 kg and 1.0 μU/mL
for women. Participants had significant decreases in
Table 1 Baseline risk factors and vascular stiffness in the SAVE trial
All (N= 339) Women (N=261) Men (N= 78)
Risk Factor Mean SD Mean SD Mean SD P-Value{
Age (years) 37.9 6.1 37.5 6.1 38.0 6.1 0.478
Weight (kg) 92.2 15.0 88.3 12.6 105.1 15.3 <0.001
BMI (kg/m2) 32.8 3.9 32.6 3.9 33.5 3.7 0.062
Heart Rate (bpm) 70.0 17.4 69.9 16.5 70.0 20.4 0.998
Total Cholesterol (mg/dL) 203.3 37.4 203.5 38.0 202.7 35.7 0.876
HDLc (mg/dL) 52.8 13.5 55.8 13.4 42.7 7.9 <.001
LDLc (mg/dL) 123.7 33.2 122.7 33.9 126.9 30.4 0.329
Triglycerides (mg/dL)† 116 (78–170) 106 (76–155) 151 (110–209) <0.001
CRP (mg/dL)† 2.6 (1.3-5.7) 2.9 (1.5-6.5) 2.2 (0.9-3.6) <0.001
Fasting Insulin (μU/mL) 14.6 8.1 14.0 6.8 16.5 11.2 0.069
HOMA-IR 3.6 2.1 3.4 1.8 4.1 2.9 0.045
Systolic BP, mm Hg 113.3 10.5 112.2 10.6 117.1 9.1 <.001
Diastolic BP, mm Hg 72.9 8.7 71.8 8.6 76.5 8.1 <.001
Mean Arterial Pressure 93.1 8.9 92.0 8.9 96.8 7.9 <.001
Ankle-Brachial Index 1.06 0.07 1.05 0.07 1.08 0.07 0.002
Race – n,% 0.013
White 273 80.5% 205 78.5% 68 87.2%
Black 54 15.9% 49 18.8% 5 6.4%
Other 12 3.5% 7 2.7% 5 6.4%
Smoking Status – n,% 0.067
Never 211 62.2% 155 59.4% 56 71.8%
Former 96 28.4% 82 31.4% 14 17.9%
Current 32 9.4% 24 9.2% 8 10.3%
Vascular Stiffness Mean SD Mean SD Mean SD
Mixed, baPWV (cm/sec) 1207.6 132.3 1194.2 126.0 1252.3 143.6 <.001
Peripheral, faPWV (cm/sec) 945.9 102.8 942.9 98.2 956.1 117.5 0.385
Central, cfPWV (cm/sec) 880.0 257.4 864.6 247.8 932.3 283.1 0.046
* Values reported are mean ± SD unless otherwise noted.
† Reported as Median (Q1-Q3) due to skewed distribution.
{ Denotes test for difference between men and women.
HOMA-IR: Homeostatic Insulin Resistance, CRP: C - reactive protein; baPWV: brachial-ankle pulse-wave velocity (n = 339); faPWV: femoral-ankle pulse-wave velocity
(n = 320); cfPWV: carotid-femoral pulse-wave velocity (n = 324).
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baPWV and cfPWV but not in faPWV over the 6-month
period (Table 2). Similar trends were seen in the men
alone; however, in women, only cfPWV decreased sig-
nificantly. The difference by gender was only significant
for baPWV, which decreased by 33.3 cm/s in men and
4.1 cm/s in women (P = 0.045).
Insulin reduction and weight loss were individually
associated with decreases in baPWV (p = 0.023 and
p = 0.040, respectively, Table 3), but not with faPWV or
cfPWV (data not shown). Individually, weight loss and
insulin reductions predicted decreases in baPWV inde-
pendent of baseline cardiometabolic risk factors, includ-
ing: age, sex, race, smoking status, BMI, SBP, HDLc,
triglycerides, CRP, fasting insulin, and baseline PWV
(p = 0.083 and 0.097, respectively). Subjects with elevated
baseline insulin (fasting insulin ≥15μU/mL) experienced
a mean decrease of 19.2 cm/sec in baPWV, compared to
an increase of 0.1 cm/sec in patient with normal baseline
insulin. After adjustment for insulin change, weight loss
was no longer significantly associated with decreases in
baPWV (p= 0.0681). There was a significant interaction
effect of insulin change and weight change (Table 3,
P < 0.001) for changes in baPWV independent of other
cardiovascular risk factors. These results for absolute
changes in insulin and weight were consistent with mod-
els where weight and insulin change were expressed as a
percent change from baseline measures. Participants
with both weight loss and insulin reductions had the
greatest improvement in baPWV (Figure 1). The PWV
data showed that individuals in the upper tertile of the
baPWV distribution experienced greater than a 50 cm/s
decrease in baPWV over six months. Reaching this
benefit was strongly predicted by both insulin change
and weight loss. Additional file 1: Figure S1 shows the
incremental benefit of weight loss and changes in insulin
on baPWV. The proportion of individuals reaching a
50 cm/s declines in baPWV was similar for those experi-
encing little/no change as those with weight loss only
(28% versus 26%, respectively). This levels of benefit was
achieved by 35% of participants with insulin reduction
only, and by 45% of those with both reduced weight and
insulin.
Discussion
This work demonstrates that both weight loss and insu-
lin reductions had direct and positive effects on arterial
stiffness, and that the strongest effect occured in indivi-
duals who simultaneously lost weight and lowered their
insulin levels. Specifically, weight loss and insulin reduc-
tions were individually associated with improvements in
baPWV independent of cardiometabolic risk factors.
The combined effect of weight loss and insulin reduction
over 6-months had a greater impact on baPWV than
weight loss or insulin reductions alone.
Weight loss has been previously shown to improve
vascular stiffness [9,15] although the mechanism under-
lying this association is unknown. Previous work from
the SAVE trial has studied various predictors of changes
in pulse-wave velocity [9]. The current analysis was
directed at studying the relationship between weight
loss, improved insulin sensitivity, and subsequent
changes in vascular stiffness. We found that the com-
bined effects of weight loss and reduction in circulating
insulin was independent of changes in other factors
related to change in pulse-wave velocity [9]. Weight loss
affects a wide variety of physiologic measures, including
insulin sensitivity and circulating insulin levels, in part,
through improved insulin homeostasis [18]. Hyperinsuli-
nemia promotes the arteriosclerotic process by instigat-
ing vascular smooth muscle cells proliferation and
migration in the vessel wall [18,22]. Recently Yue et al.,
in a study of people with type 2 diabetes, found that
poor glycemic control was associated with lower circu-
lating levels of endothelial progenitor cells and higher
baPWV [23]. PWV is also associated with other mea-
sures of arterial architecture, including vascular thick-
ness [9,24]. Results from the ongoing Vaso Risk study
[25] have the potential to provide more detail on the re-
lationship between diabetes, glycemic control and arter-
ial stiffness.
The observed results differ by location within the ar-
terial tree. Weight loss and insulin reduction were
Table 2 Six-month changes in vascular stiffness and risk
factors during the SAVE trial
SAVE (N= 272)
Vascular Stiffness Mean SD % Change
Δ baPWV (cm/s), mixed −11.6† 91.5 −0.7
Δ faPWV (cm/s), peripheral +5.8 91.9 +0.9
Δ cfPWV (cm/s), central −51.9† 303.3 −1.6
Potential Covariates
Weight (kg) −7.0 5.9 −7.6
BMI (kg/m2) −2.0 2.0 −7.0
HDLc (mg/dL) 0.9 8.0 3.1
LDLc (mg/dL) −2.9 25.7 −0.3
Triglycerides (mg/dL) −18.7 60.1 −9.1
CRP (mg/dL) −1.0 4.9 −38.0
Fasting Insulin (μU/mL) −1.3 6.9 −0.7
Systolic BP, mm Hg −2.6 8.2 −2.0
Diastolic BP, mm Hg −1.5 7.7 −1.4
Mean Arterial Pressure −2.0 7.2 −1.9
* Values reported represent the crude mean change from baseline PWV and
the % change from baseline PWV.
† change from zero, p < 0.05.
baPWV: brachial-ankle pulse-wave velocity.
faPWV: femoral-ankle pulse-wave velocity.
cfPWV: carotid-femoral pulse-wave velocity.
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associated with reductions in baPWV, a mixed measure
of stiffness, but not with changes in purely central or
peripheral measures. These data suggest improvements
in weight and insulin are likely to be systemic and can
be seen in measures of the vasculature that incorporate
both central and peripheral PWV. While central mea-
sures of PWV changed in response to the lifestyle inter-
vention in SAVE, weight loss and insulin reductions
were not associated with changes in these measures. The
individual and combined effects of weight loss and insu-
lin reductions were more pronounced in the mixed
measure than the purely central and peripheral mea-
sures. Our findings suggest that using mixed measures
of PWV that take into account both central and periph-
eral vascular changes is the best representation of the
effects of weight and insulin change on arterial stiffness.
These findings add to previous studies that show weight
loss is associated with improvements in both central
[5,26] and mixed [9] measures of arterial stiffness. The
effects of weight loss and insulin declines are more
apparent throughout the vasculature than in central and
peripheral arterial beds alone.
It is possible that we only detected significant differ-
ences in baPWV because this mixed measure of arterial
stiffness is more sensitive to short-term vascular remodel-
ing. However, it is also possible that we did not see effects
in cfPWV as a result of its large variances at baseline and
follow up, resulting in limited statistical power to detect
small changes over time. The addition of carotid and fem-
oral probes makes the PWV protocol more difficult to
execute and may result in more error in the peripheral
measures especially in obese individuals [27]. In previous
analysis, our group identified factors other than changes
in insulin as potential predictors of cfPWV [9]. Further-
more, the removal of potential outliers (thirty individuals
with change in cfPWV >400 cm/sec) had little effect on
the results of these analyses and weight loss and insulin
reduction still did not predict changes cfPWV.
In this analysis, adjustment for insulin change fully
attenuated the association between weight loss and
Table 3 Linear regression analyses predicting six-month changes in brachial-ankle pulse-wave velocity in the SAVE
trial
Predictor Unadjusted Associations1 Model 22 Model 33
β 95% CI β 95% CI β 95% CI
Insulin Reduction −1.71** (−0.08, -3.34) −0.83 (0.77, -2.43) 3.71 (2.52, 5.00)
Weight Loss −2.14** (−0.32, -3.98) −1.55* (0.57, -3.61) −0.95 (−1.92 ,0.02)
Interaction – – – – −0.43*** (−0.31, -0.55)
*P < 0.10, **P < 0.05, ***P < 0.001.
1 In the unadjusted model, the β term represents the predicted change in pulse-wave velocity (cm/s) per unit decrease in insulin (μU/mL) and weight (kg).
2 In the second column of multivariate models, the β term represents the predicted change in pulse-wave velocity (cm/s) per unit decrease in insulin (μU/mL)
and weight (kg) when adjusting for age, sex, race, smoking status, mean arterial pressure, HDL cholesterol, triglycerides, CRP, baseline baPWV and change in mean
arterial pressure. This is one model with both weight loss and insulin change simultaneously plus covariates.
3 In the third column of multivariate models, the β term represents the predicted change in pulse-wave velocity (cm/s) for a simultaneous decrease in insulin
(μU/mL) and weight (kg) when adjusting for age, sex, race, smoking status, mean arterial pressure, HDL cholesterol, triglycerides, CRP, baseline baPWV and change
in mean arterial pressure. This is one model with both weight loss and insulin change simultaneously plus their interaction plus covariates.
baPWV: brachial-ankle pulse-wave velocity.
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Figure 1 Adjusted* mean changes in baPWV by insulin- and weight-loss groups in the SAVE trial. Baseline and 6-month mean PWV
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decreases in baPWV. This evidence builds on the find-
ings of previous studies that show insulin levels and
impaired fasting glucose are more related to peripheral
measures of PWV than BMI, weight and weight loss. A
study of 697 non-diabetic adults found increased
baPWV in subjects with impaired fasting glucose, inde-
pendent of BMI [28]. While these results imply that
there is a connection between impaired fasting glucose
and mixed measures of arterial stiffness, their study did
not measure fasting insulin levels and could not con-
clude that the effect of impaired glucose levels on
baPWV were independent of insulin levels [28]. Zhang
et al., found that Chinese people with type 2 diabetes
had increased central and peripheral PWV compared to
controls, and fasting glucose was a determinant of per-
ipheral artery stiffness. This study did not measure fast-
ing insulin levels or relate these levels to neither fasting
glucose levels or arterial stiffness [29]. Recently,
Rudofsky et al. reported the effects of 12 weeks of weight
loss intervention in 21 obese and non-diabetic partici-
pants on PWV, measured by finger photoplethysmogra-
phy [15]. They showed that improvements in PWV were
associated with improvements in HOMA-IR only, and
not with weight loss.
The effect of weight loss and insulin reduction on
baPWV was stronger in men. The differential effect of
sex is likely explained by differences in the baseline char-
acteristics of men and women recruited for the SAVE
trial. At SAVE baseline, men had greater risk factors for
CVD and diabetes and higher baseline PWV than
women. As a result, the SAVE intervention had a greater
impact on weight loss and cardiometabolic risk factors
in men. In the first six months of the SAVE trial, men
lost more weight than women (9.3 kg vs. 5.8 kg) and had
more than twice the decrease in insulin (2.5 μU/mL vs.
1.0 μU/mL). Our findings suggest that the weight loss
intervention was more successful in men than women,
as has been reported previously in the literature [5,30].
The relatively small numbers of men and African-
Americans in the SAVE trail limits our ability to
generalize to these groups and to stratify all analyses by
gender or race, although adjustment for these factors
was made. Additionally our study only focused on the 6-
month change in weight, insulin and PWV. Consistent
with other findings, the SAVE study found that weight
loss plateaus between 6–12 months of follow up; conse-
quently, we limited our analysis to 6-month data to
avoid instances of weight re-gain in study subjects.
The SAVE trial provides longitudinal assessment of ar-
terial stiffness and cardiometabolic risk factors. While
the participants in SAVE were overweight or obese, they
were generally healthy, without impaired fasting glucose
or diabetes [8]. The SAVE trial focuses on this segment
of the population enabling the study of the effects of
obesity and the early stages of insulin resistance prior to
the onset of diabetes. Obese individuals with hyperinsu-
linemia are potentially ideal targets for such an interven-
tion targeted to lower PWV. Our study shows that in
terms of cardiovascular risk, people with hyperinsuline-
mia and obesity will likely show the most benefit from a
weight loss intervention. Further, the measurement of
regional PWV provides additional insight into the corre-
lates of arterial stiffness along the vasculature, which a
single assessment could not provide. Future studies of
weight loss and changes in arterial stiffness should
utilize additional measures of metabolic syndrome [31]
and diabetes risk factors [32] to elucidate the relation-
ships between weight loss, diabetes risk factors and ar-
terial stiffness.
Conclusions
Young overweight and obese adults who lower their in-
sulin levels and lose weight over 6 months experience
decreased vascular stiffness, measured by PWV. This im-
provement in vascular stiffness was greatest among indi-
viduals who experienced both weight loss and insulin
reduction. The potential effects of these reductions on
arterial stiffness may be more pronounced throughout
the vasculature than in the individual vascular beds.
Overweight and obese individuals with elevated insulin
levels are likely to have the greatest improvement in ar-
terial stiffness from clinical interventions focused on
weight loss and decreased blood insulin levels.
Additional file
Additional file 1: Figure S1. Proportion of subjects experiencing a
decrease in baPWV of ≥50 cm/sec by insulin- and weight-loss groups in
the SAVE trial. This more clearly shows that a greater proportion of the
“Weight Decrease and Insulin Decrease” had a baPWV decrease of 50 cm/
sec (*Note: I chose 50 as somewhat of an arbitrary cutoff, but it seems to
provide a decent # of patients in all categories and also will appeal to
readers that just like round numbers). There is also a statistically
significant difference between the groups in a global test (p = 0.015), so it
might be appealing to present this figure with a p-value.
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